Business Segments · D&A
MEDTECH — D&A
Johnson & Johnson MEDTECH — D&A decreased by 2.5% to $903.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.0%, from $836.00M to $903.00M. Over 4 years (FY 2021 to FY 2025), MEDTECH — D&A shows an upward trend with a 11.2% CAGR.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2017
Last reportedQ1 2026Apr 22, 2026
Rolls up toD&A
How to read this metric
Higher values indicate a larger asset base or significant recent capital investments that are being expensed over time.
Detailed definition
This is the combined non-cash expense representing the allocation of the cost of tangible and intangible assets over the...
Peer comparison
Standard operating expense metric found in segment-level cash flow and income statements.
Metric ID:
jnj_segment_medtech_depreciation_and_amortizationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $571.50M | $571.50M | $571.50M | $575.50M | $575.50M | $575.50M | $575.50M | $735.75M | $735.75M | $735.75M | $735.75M | $746.00M | $806.00M | $818.00M | $867.00M | $836.00M | $842.00M | $886.00M | $926.00M | $903.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.7% | +0.0% | +0.0% | +0.0% | +27.8% | +0.0% | +0.0% | +0.0% | +1.4% | +8.0% | +1.5% | +6.0% | -3.6% | +0.7% | +5.2% | +4.5% | -2.5% |
| YoY Change | — | — | — | — | +0.7% | +0.7% | +0.7% | +27.8% | +27.8% | +27.8% | +27.8% | +1.4% | +9.5% | +11.2% | +17.8% | +12.1% | +4.5% | +8.3% | +6.8% | +8.0% |
Range$571.50M – $926.00M
CAGR+10.1%
Avg YoY Growth+12.1%
Median YoY Growth+8.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's medtech — d&a?
- Johnson & Johnson (JNJ) reported medtech — d&a of $903.00M in Q1 2026.
- How has Johnson & Johnson's medtech — d&a changed year-over-year?
- Johnson & Johnson's medtech — d&a increased by 8.0% year-over-year, from $836.00M to $903.00M.
- What is the long-term trend for Johnson & Johnson's medtech — d&a?
- Over 4 years (2021 to 2025), Johnson & Johnson's medtech — d&a has grown at a 11.2% compound annual growth rate (CAGR), from $2.29B to $3.49B.
- What does medtech — d&a mean?
- The total non-cash expense for the wear and tear of equipment and the expiration of intangible assets in the medical technology segment.